Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer.

Objectives: In order to screen for gastric cancer effectively, its interval should be set according to the risk. This study aimed to determine whether risk stratification is possible using the data obtained from medical examination or endoscopic findings.

Methods: First, subjects who underwent both cancer screening and medical examination from 2009 to 2015 and underwent cancer screening once more by 2016 were studied.

A survey about further work-up for cases with positive sputum cytology during lung cancer mass screening in Ishikawa Prefecture, Japan: a retrospective analysis about quality assurance of lung cancer screening.

Objective: In cancer screening programs, performing appropriate further work-up is essential. In order to elucidate whether the further work-up for the subjects with positive screening results by sputum cytology was performed appropriately, the present study was conducted as the first large-scale thorough survey in Japan.

Methods: All of the lung cancer screening records from 2007 to 2012 in Ishikawa Prefecture were reviewed.

History of distal gastrectomy prevents metabolic syndrome and chronic kidney disease.

Aims: Chronic kidney disease (CKD) due to metabolic syndrome has recently become a social problem in Japan. In this report, the associations between the history of distal gastrectomy (DG) and the incidence of metabolic syndrome or CKD were evaluated.

Methods: Arteriosclerosis-related factors were compared among patients with a history of DG who were <70 years old (n=41) and controls selected at random (n=410) after matching for age and sex.

Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.

Atorvastatin is a powerful new synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor currently in clinical use. Its effects on plasma levels of factor VII were examined in 30 hyperlipidemic patients. After 12 weeks of atorvastatin treatment, factor VII activity (FVIIc) and factor VII antigen (FVIIag) levels had decreased by 13% (p < 0.